Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2019

View Archived Issues

Plaques form early, and differently, in Trem2-associated Alzheimer's disease

PD-1-Fc-OX40L fusion protein simultaneously blocks immune checkpoint pathways and activates TNFRs

PAMVAC vaccine demonstrates safety and immunogenicity in first-in-human study

Positive results presented for second cohort of phase II study of ZGN-1061

Microtubule polymerization inhibitor prodrugs identified at the University of Maryland

Daiichi Sankyo patents histone acetyltransferase p300/CREB-binding protein inhibitors

Gruenenthal presents new phosphodiesterase PDE4B inhibitors

Birdie Biopharmaceuticals discovers resiquimod salts

Promentis Pharmaceuticals initiates phase II studies of SXC-2023

APP's day job: amyloid precursor protein suppresses GABA transmission

Sarepta Therapeutics initiates phase II study of SRP-9001 in patients with DMD

YF-ZIKprM/E vaccine protects against Zika infection and congenital malformations in mouse models

MiR-20a/miR-106a identified as a therapeutic target for preventiing CRC progression

Patient enrollment ongoing in Roche's phase III study of RO-7234292 in Huntington's disease

NHS-IL-12 demonstrates safety and early clinical immune-related activity

AbbVie begins phase II trial of elezanumab for relapsing MS

Novartis begins first-in-human trial of NJH-395 in non-breast HER2-positive advanced malignancies

iJak-381 demonstrates efficacy in rodent models of asthma

FDA issues complete response letter for sacituzumab govitecan BLA for metastatic TNBC

T-PEP funding supports Aquinnah Pharmaceuticals work in tauopathies

Global Alliance for TB Drug Development begins phase I trial of TBI-223 in healthy subjects

CorMedix reports topline results from interim analysis of phase III trial of Neutrolin

U.S. clearances granted for phase III trial of ranibizumab biosimilar Xlucane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...